Pfizer Service Company BV Pharmaceutical Import Profile — Belgium (DGFT 2022–2026)

Name: Pfizer Service Company BV Pharmaceutical Import Records from India — 5 Products, $2.2M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Pfizer Service Company BV — Pharmaceutical Importer Profile (2026) | 5 Products, $2.2M Trade | TransData Nexus

Pfizer Service Company BV

Pharmaceutical Importer · Belgium · Oncology Focus · $2.2M Total Trade · DGFT Verified

Pfizer Service Company BV is a pharmaceutical importer based in Belgium with a total trade value of $2.2M across 5 products in 3 therapeutic categories. Based on 47 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Pfizer Service Company BV sources from 2 verified Indian suppliers, with Zydus Hospira Oncology Private Limited accounting for 78.5% of imports.

Pfizer Service Company BV — Import Portfolio & Supplier Network

Pfizer Service Company BV import network — 5 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Pfizer Service Company BV?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Zydus Hospira Oncology Private Limited	$1.6M	57	78.5%
Alembic Pharmaceuticals Limited	$450.0K	9	21.5%

Pfizer Service Company BV sources from across .

What Formulations Does Pfizer Service Company BV Import?

Formulation	Value	Ships
Azithromycin tablets USP 250 MG TAB (azithromycin tablets 250 mg500s pfizer)	$250.0K	5
Azithromycin tablets 250 MG 500s	$200.0K	4
Gemcitabine injection 2g	$190.7K	4
Docetaxel INJ.160MG-uspremier-f000052363	$100.0K	2
Gemcitabine INJ. 2g au/nz -	$100.0K	2
Gemcitabine INJ.200MG-es-f000057726	$50.0K	1
Docetaxel INJ. 80 MG us	$50.0K	1
Cytarabine INJ. 2g	$50.0K	1
Pentostatin for INJ.10MG-it-f000056985	$50.0K	1
Cytarabine injection 2g	$50.0K	1
Bleo for INJ.USP 30unitsn+	$50.0K	1
Oxaliplatin INJ. 200MG jp	$50.0K	1
Irinotecan hcl INJ.100MG-hk-f000035889	$50.0K	1
Irinotecan hcl INJ. 100MG-sg-f000054116	$50.0K	1
Oxaliplatin INJ. 50MG th	$50.0K	1

Pfizer Service Company BV imports 51 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 5 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Gemcitabine	Oncology	$750.0K	15	1.6%	9
2	Docetaxel	Oncology	$500.0K	10	1.3%	4
3	Irinotecan	Oncology	$425.8K	11	1.0%	18
4	Cytarabine	Advanced Oncology	$252.6K	6	2.4%	11
5	Azithromycin	Antibiotics	$250.0K	5	0.1%	8

Pfizer Service Company BV imports 5 pharmaceutical products across 3 categories into Belgium totaling $2.2M.

Pfizer Service Company BV — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Pfizer Service Company BV is a prominent pharmaceutical wholesaler and distributor headquartered in Zaventem, Belgium. Established on August 30, 2002, the company operates under the Belgian VAT number BE0478.242.365. With a workforce of approximately 242.9 full-time equivalents, Pfizer Service Company BV reported a revenue of €34.09 billion in 2024, marking a 12% decrease from the previous year. (companyweb.be) The company's primary activity involves the wholesale distribution of pharmaceutical and medical products, positioning it as a key player in Belgium's pharmaceutical supply chain.

2Distribution Network

Pfizer Service Company BV's distribution network is strategically located to serve the Belgian market effectively. The company's main office is situated at Hermeslaan 11, 1932 Zaventem, Belgium. (companyweb.be) While specific details about additional warehouse locations and logistics capabilities are not publicly disclosed, the company's substantial revenue and workforce suggest a well-established infrastructure capable of managing extensive distribution operations.

3Industry Role

In Belgium's pharmaceutical supply chain, Pfizer Service Company BV functions primarily as a wholesaler and distributor. The company imports a diverse range of pharmaceutical products, including finished formulations such as tablets, capsules, syrups, and injections, from various international suppliers. This role is crucial in ensuring the availability of a wide array of pharmaceutical products to meet the needs of healthcare providers and patients across Belgium.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Pfizer Service Company BV

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Pfizer Service Company BV's sourcing strategy exhibits a notable concentration, with a significant portion of its pharmaceutical imports originating from India. Between 2022 and 2026, the company imported finished pharmaceutical formulations valued at $2.2 million from India, encompassing 47 shipments and 51 unique formulations across five products and three therapeutic categories. The top five imported products include Gemcitabine ($750K), Docetaxel ($500K), Irinotecan ($426K), Cytarabine ($253K), and Azithromycin ($250K). The primary suppliers from India are Zydus Hospira Oncology Private Limited, accounting for 78.5% of the imports, and Alembic Pharmaceuticals Limited, contributing 21.5%. This sourcing pattern indicates a strategic choice to leverage India's manufacturing capabilities, particularly in oncology and antibiotic medications, to meet the Belgian market's demands.

2Supply Chain Resilience

The resilience of Pfizer Service Company BV's supply chain, particularly concerning its Indian suppliers, is a critical factor in maintaining a consistent product supply. The company's reliance on two primary suppliers for a substantial portion of its imports suggests a level of dependency that could pose risks in the event of supply disruptions. However, the diversity of 51 unique formulations indicates a degree of flexibility in product offerings. To enhance supply chain resilience, it would be prudent for Pfizer Service Company BV to consider diversifying its supplier base and establishing contingency plans to mitigate potential disruptions.

Importing Pharmaceuticals into Belgium — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Belgium

1Regulatory Authority & Framework

In Belgium, the Federal Agency for Medicines and Health Products (FAMHP) serves as the primary regulatory authority overseeing the importation and distribution of pharmaceutical products. The legal framework governing pharmaceutical imports is primarily outlined in the Royal Decree of 14 December 2006, which regulates medicines for human use. This decree establishes the conditions under which medicinal products can be imported, including requirements for marketing authorization, quality standards, and safety assessments. Additionally, the Royal Decree of 4 September 2022 amended the Royal Decree of 19 April 2001, easing conditions for parallel imports of pharmaceuticals by removing the requirement that imported medicinal products must have the same therapeutic indications as the Belgian reference product.

2Import Licensing & GMP

Import licensing in Belgium is governed by the FAMHP, which requires wholesalers to obtain an authorization to import medicinal products. This authorization ensures that imported products meet Belgian regulatory standards. The Good Manufacturing Practice (GMP) certification is a critical component of this process. Belgium recognizes GMP certifications from the European Union (EU GMP), the World Health Organization (WHO GMP), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Wholesalers must ensure that their suppliers hold valid GMP certifications from these recognized bodies to comply with Belgian import regulations. (famhp.be)

Pfizer Service Company BV — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Pfizer Service Company BV's product strategy focuses on importing pharmaceutical formulations that address critical therapeutic needs in Belgium, particularly in oncology and antibiotic treatments. The company's top five imported products—Gemcitabine, Docetaxel, Irinotecan, Cytarabine, and Azithromycin—are essential in the treatment of various cancers and infections. This strategic focus aligns with the high demand for effective cancer therapies and antibiotics in the Belgian healthcare system, ensuring that Pfizer Service Company BV contributes significantly to patient care by providing access to these vital medications.

2Sourcing Profile

Pfizer Service Company BV's sourcing strategy emphasizes the procurement of generic pharmaceutical formulations from India, leveraging the country's robust manufacturing capabilities and cost advantages. The company's imports from India encompass a diverse range of formulations, indicating a preference for ready-to-use products that meet international quality standards. This approach allows Pfizer Service Company BV to offer a comprehensive product portfolio to the Belgian market, catering to various therapeutic areas and patient needs.

3Market Positioning

Seller's Guide — How to Become a Supplier to Pfizer Service Company BV

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Pfizer Service Company BV, particularly in the oncology and antibiotic therapeutic areas. The company's existing sourcing pattern indicates a preference for high-quality, cost-effective generic formulations, which aligns with the capabilities of Indian pharmaceutical manufacturers. To capitalize on this opportunity, Indian exporters should focus on ensuring consistent product quality, compliance with international regulatory standards, and the ability to meet the logistical demands of the Belgian market.

2Requirements & Qualifications

Indian exporters aiming to supply Pfizer Service Company BV and the Belgian market must adhere to several key requirements. Products must be manufactured in facilities holding valid GMP certifications from recognized bodies such as EU GMP, WHO GMP, or PIC/S. Additionally, products must comply with Belgian labeling requirements, including translations into Dutch, French, and German. Serialization mandates must also be met to ensure traceability and prevent counterfeit products. Furthermore, exporters must obtain the necessary import licenses from the FAMHP, ensuring that all regulatory conditions are satisfied for the Belgian market.

How to Approach

Frequently Asked Questions — Pfizer Service Company BV

What products does Pfizer Service Company BV import from India?

Pfizer Service Company BV imports 5 pharmaceutical products across 3 categories. Top imports: Gemcitabine ($750.0K), Docetaxel ($500.0K), Irinotecan ($425.8K), Cytarabine ($252.6K), Azithromycin ($250.0K).

Who supplies pharmaceuticals to Pfizer Service Company BV from India?

Pfizer Service Company BV sources from 2 verified Indian suppliers. The primary supplier is Zydus Hospira Oncology Private Limited (78.5% of imports, $1.6M).

What is Pfizer Service Company BV's total pharmaceutical import value?

Pfizer Service Company BV's total pharmaceutical import value from India is $2.2M, based on 47 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Pfizer Service Company BV focus on?

Pfizer Service Company BV imports across 3 categories. The largest: Oncology (76.9%), Advanced Oncology (11.6%), Antibiotics (11.5%).

Get Full Pfizer Service Company BV Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.